- PR Newswire
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of a poster highlighting new preclinical data on NKTR-0165 at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress.
- Simply Wall St.
Nektar Therapeutics' (NASDAQ:NKTR) investors will be pleased with their stellar 130% return over the last year
Nektar Therapeutics ( NASDAQ:NKTR ) shareholders might be concerned after seeing the share price drop 11% in the last...
- PR Newswire
Nektar Management to Present at Upcoming Investor Conferences
Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at upcoming investor conferences:
© 2024 Yahoo. All rights reserved.